The week in pharma: action, reaction and insight – week to June 28, 2024

By Barbara Obstoj-Cardwell. Editor

Among important research news last week, US RNA specialist Alnylam Pharmaceuticals released positive Phase III data on its Amvuttra (vutrisiran) in hereditary transthyretin-mediated amyloidosis. On the regulatory front, the US Food and Drug Administration (FDA) approved Verona Pharmaceuticals’ Ohtuvayre for chronic obstructive pulmonary disease (COPD), but US biotech Rocket Pharmaceuticals hit a setback on the development of its gene therapy Kresladi as the FDA issued a complete response letter (CRL). Also of note last week, Denmark’s Novo Nordisk announced a $4.1 billion investment plan in North Carolina, USA, to expand production of treatments for obesity and other chronic diseases.

Alnylam: Updating mode for Amvuttra’s day in the sun